Advertisement

Alpha-2 Adrenergic Receptor Agonists

  • Esen Özkaya
  • Kurtuluş Didem Yazganoğlu
Chapter

Abstract

Alpha-2 adrenergic receptor agonists include clonidine, guanfacine, guanabenz, methyldopa, rilmenidine, and moxonidine. These are centrally active antihypertensive drugs.

Keywords

Alpha-2 adrenergic receptor agonist Methyldopa Clonidine Photosensitivity Lupus Lichenoid Eczema Psoriasis/Psoriasiform Xerostomia 

References

  1. 1.
    Breckenridge A, Dollery CT, Worlledge SM, Holborow EJ, Johnson GD. Positive direct Coombs tests and antinuclear factor in patients treated with methyldopa. Lancet. 1967;2:1265–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Nordstrom DM, West SG, Rubin RL. Methyldopa-induced systemic lupus erythematosus. Arthritis Rheum. 1989;32:205–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Dupont A, Six R. Lupus-like syndrome induced by methyldopa. Br Med J (Clin Res Ed). 1982;285:693–4.CrossRefGoogle Scholar
  4. 4.
    Harrington TM, Davis DE. Systemic lupus-like syndrome induced by methyldopa therapy. Chest. 1981;79:696–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Sherman JD, Love DE, Harrington JF. Anemia, positive lupus and rheumatoid factors with methyldopa. A report of three cases. Arch Intern Med. 1967;120:321–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Frishman WH, Brosnan BD, Grossman M, Dasgupta D, Sun DK. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002;10:337–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Mota AV, Vasconcelos C, Correia TM, Barros MA, Mesquita-Guimaraes J. Rilmenidine-induced photosensitivity reaction. Photodermatol Photoimmunol Photomed. 1998;14:132–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Vaillant L, Le Marchand D, Grognard C, Hocine R, Lorette G. Photosensitivity to methyldopa. Arch Dermatol. 1988;124:326–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2942–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Burry JN, Kirk J. Letter: Lichenoid drug reaction from methyldopa. Br J Dermatol. 1974;91:475–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Burry JN. Ulcerative lichenoid eruption from methyldopa. Arch Dermatol. 1976;112:880.PubMedCrossRefGoogle Scholar
  12. 12.
    Holt PJ, Navaratnam A. Lichenoid eruption due to methyldopa. Br Med J. 1974;3:234.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Stevenson CJ. Lichenoid eruptions due to methyldopa. Br J Dermatol. 1971;85:600.PubMedCrossRefGoogle Scholar
  14. 14.
    Hay KD, Reade PC. Methyldopa as a cause of oral mucous membrane reactions. Br Dent J. 1978;145:195–203.PubMedCrossRefGoogle Scholar
  15. 15.
    Gonzalez JG, Marcus MD, Cruz DJ. Giant cell lichenoid dermatitis. J Am Acad Dermatol. 1986;15:87–92.PubMedCrossRefGoogle Scholar
  16. 16.
    Heid E, Samsoen M, Juillard J, Eberst E, Foussereau J. Papulo-vesicular endogenous eruptions induced by methyldopa and clofibrate. Ann Dermatol Venereol. 1977;104:494–6.PubMedGoogle Scholar
  17. 17.
    Church R. Eczema provoked by methyl dopa. Br J Dermatol. 1974;91:373–8.PubMedCrossRefGoogle Scholar
  18. 18.
    van Joost T, Faber WR, Manuel HR. Drug-induced anogenital cicatricial pemphigoid. Br J Dermatol. 1980;102:715–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Wilkin J. Exacerbation of psoriasis during clonidine therapy. Arch Dermatol. 1981;117:4.PubMedCrossRefGoogle Scholar
  20. 20.
    Prisant LM. Transdermal clonidine skin reactions. J Clin Hypertens (Greenwich). 2002;4:136–8.CrossRefGoogle Scholar
  21. 21.
    Crivellaro MA, Bonadonna P, Dama A, Senna G, Passalacqua G. Skin reactions to clonidine: not just a local problem. Case report. Allergol Immunopathol (Madr). 1999;27:318–9.Google Scholar
  22. 22.
    Doe N, Seth S, Hebert LA. Skin depigmentation related to transdermal clonidine therapy. Arch Intern Med. 1995;155:2129.PubMedCrossRefGoogle Scholar
  23. 23.
    Wiser TH, Kazakis AM, LaCivita CL. Transdermal clonidine: an association with recurrent herpes simplex and hyperpigmentation. J Am Acad Dermatol. 1987;17:143–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Litt JZ. Drug eruption reference manual. 19th ed. Boca Raton: CRC Press (Taylor and Francis Group); 2013.Google Scholar
  25. 25.
    Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Crit Rev Oral Biol Med. 2004;15:28–46.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolf R, Tamir A, Werbin N, Brenner S. Methyldopa hypersensitivity syndrome. Ann Allergy. 1993;71:166–8.PubMedGoogle Scholar
  27. 27.
    Brody HJ, Cohen M. Black tongue secondary to methyldopa therapy. Cutis. 1986;38:187–8.PubMedGoogle Scholar
  28. 28.
    Wells JD, Kurtay M, Lochner JC, George WL. Letter: Granulomatous skin lesions and alpha-methyldopa. Ann Intern Med. 1974;81:701–2.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Esen Özkaya
    • 1
  • Kurtuluş Didem Yazganoğlu
    • 1
  1. 1.Department of Dermatology and VenereologyIstanbul University Istanbul Medical FacultyIstanbulTurkey

Personalised recommendations